Divis Laboratories Ltd News
Sun Pharma sees Golden Cross; other pharma stocks with similar pattern
Technically, the term 'Golden Cross' has bullish implications with short-term support seen moving higher. Apart from Sun Pharma, Aurobindo Pharma and Divi's Labs too witnessed this formation recently.
 "Sun Pharma sees Golden Cross; other pharma stocks with similar pattern")
Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds
Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.
 "Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds")
10 stocks with maximum upside this Diwali; Don't miss the market fireworks!
Leading the list is GNG Electronics (Target: ₹482 | Upside: 52%), named by Nirmal Bang, which expects robust growth as the company benefits from the govt's 'Make in India' thrust on electronics mfg.
 "10 stocks with maximum upside this Diwali; Don't miss the market fireworks!")
Divis Labs rallies 13% in 1 week; What's driving pharma stock?
Divis stock gained 2% in Monday's intra-day deals. Reports suggest the company is well positioned to benefit from emerging trends across both API and CDMO domains through innovation and capex.
 "Divis Labs rallies 13% in 1 week; What's driving pharma stock?")
Sun, Lupin, Dr Reddy's drop up to 4%; why are pharma stocks falling today?
Pharma shares crash: In the past four weeks, the Nifty Pharma index has slipped 5 per cent, as against 0.19 per cent decline in the Nifty 50.
 "Sun, Lupin, Dr Reddy's drop up to 4%; why are pharma stocks falling today?")
Jefferies upbeat on India CRDMO; initiates Buy on Cohance; upgrades Divi's
Jefferies is optimistic on India's CRDMO sector, given its evolution from quasi-chemical firms into strategic partners for innovators; check more details
 "Jefferies upbeat on India CRDMO; initiates Buy on Cohance; upgrades Divi's")
Divi's Labs falls 4% after Q1 miss, analysts trim estimates; check details
Divi's Laboratories reported a 14 per cent year-on-year jump in revenue at ₹2,410 crore in Q1FY26, compared to ₹2,118 crore in the year-ago period
Nifty Pharma down 1.5%: Granules, Biocon lead with over 2% fall; Here's why
Pharma stocks fell after Trump said tariffs will be imposed within a week, rising up to 250 per cent in 12-18 months
 "Nifty Pharma down 1.5%: Granules, Biocon lead with over 2% fall; Here's why")
Divis Labs bucks weak pharma shares trend; hits new high on strong Q1 hopes
In the past six months, the Divis Labs stock has outperformed the market by surging 18 per cent, as against 1.4 per cent fall in the BSE Healthcare index and 7 per cent rise in the BSE Sensex.
